Oddly, Juno Therapeutics Is Jumping 11.3% Today
Despite a 6.1 million-share follow-on public stock offering, shares of Juno Therapeutics (NASDAQ: JUNO) are rallying 11.3% higher at 3 p.m. EDT.
Juno Therapeutics shares have been rallying since competitor Gilead Sciences (NASDAQ: GILD) acquired Kite Pharma, and competitor Novartis (NYSE: NVS) secured approval for Kymriah, the first chimeric antigen receptor T-cell (CAR-T) therapy to win a regulatory green light from the U.S. Food and Drug Administration.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Gilead Sciences Inc Stock
€119.60
-0.570%
The stock is an absolute favorite of our community with 67 Buy predictions and no Sell predictions.
With a target price of 128 € there is a slightly positive potential of 7.02% for Gilead Sciences Inc compared to the current price of 119.6 €.
